A molecular platform for reprogramming immune responses has been designed by researchers from the Children’s Hospital of Philadelphia (CHOP) and Stanford University. TRACeR-I can be used to develop cancer treatments by either directly modifying immune cells, such as T cells, or by creating proteins that help immune cells locate cancer cells. The platform uses high affinity, specific binders to peptide-MHC complexes.